T2 Biosystems Inc. buy tamam
Zusammenfassung
Diese Einschätzung wurde am 03.12.18 mit einem Endkurs von 200,25 € beendet. Die BUY Einschätzung von tamam schloss mit einer Rendite von -45,59 %. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| T2 Biosystems Inc. | - | - | - | - |
| iShares Core DAX® | 1,28 % | 1,03 % | 11,23 % | 16,27 % |
| iShares Nasdaq 100 | -2,46 % | -4,65 % | 23,18 % | 39,42 % |
| iShares Nikkei 225® | -2,01 % | -2,09 % | 6,75 % | 6,54 % |
| iShares S&P 500 | -0,66 % | -1,25 % | 22,52 % | 40,22 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion T2 Biosystems Inc. diskutieren
T2 is highly underpenetrated in its core markets
This week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4 billion to over $3 billion. T2 is highly underpenetrated in its core markets, but feels it can now penetrate the broader $1.5 billion-$2.0 billion bacterial sepsis market with an immediate entry into the hospital emergency departments, which the analyst values at $300 million.
This is a huge development. First, this panel will reduce the time to hours from days it currently takes to process a sample to determine if sepsis is present.
This deadly infection that takes numerous forms kills more people in the United States than prostrate cancer, AIDS and breast cancer combined yet gets little mention in the press. It is a continuing scourge made worse by the overuse of antibiotics resulting in more and more drug resistant forms of this type of infection. In trials, T2's new panel provided 90% sensitivity (correctly identifying true positives) and 98% specificity (correctly identifying true negatives)